Skip to main content
S&P 5007,684.94-0.44%DOW52,802.88-1.14%NASDAQ26,445.10-0.23%BTC$78,327.00-1.11%ETH$2,480.93-0.48%GOLD$4,430.00-1.04%OIL$92.84+1.49%
Smart Investors Daily
IO

NASDAQ · IOBT

IO Biotech, Inc.

Healthcare · Biotechnology

$0.05

Down-$0.00 (-27.59%)

Updated Sep 8, 2026, 4:33 PM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
61.39M
P/E ratio
-0.65
Dividend yield
0.00%
52-week range
$0.03 – $2.79
Volume
481.59M
Avg. volume
3.75M

Price performance

IOBT price history

1M range · 0 trading sessions · Daily adjusted prices

IOBT does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest IOBT news

The latest Smart Investors Daily articles mentioning IOBT.

Stock researchCompany · Overview

IOBT research

Overview

Company profile and research snapshot.

Company profile

IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$3.00
Implied upside
—
Analysts
—
IOBT recent ratings
DateFirmRatingTarget
Jan 26, 2026Piper SandlerNeutral—
Oct 22, 2025Piper SandlerOverweight—
Sep 30, 2025TD CowenHold—
Sep 29, 2025HC Wainwright & Co.Neutral—
Aug 12, 2025Morgan StanleyOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Feb 18, 2026

Cancer Vaccines Competitive Landscape Report 2026: Comprehensive Insights About 250+ Companies and 300+ Drugs - Collaborations and Licensing by Key Players Like Moderna, Merck, and IO Biotech

The cancer vaccine market presents opportunities in personalized and therapeutic vaccines, innovations in delivery strategies, and combination therapies. Collaborations and licensing by key players like Moderna, Merck, and IO Biotech drive industry progression. Challenges remain in broadening efficacy and optimizing delivery platforms.Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "Cancer Vaccines - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. This report offe

Yahoo · Jan 30, 2026

IO Biotech Provides Corporate Update

Raymond James engaged as financial advisorReduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that it has retained Raymond James & Associates, Inc. to serve as exclusive financial advisor to assist the company in its previously announced exploration of strategic alternatives. The company also announced that it

Yahoo · Jan 27, 2026

Piper downgrades IO Biotech amid strategic alternatives evaluation

Piper Sandler Friday night downgraded IO Biotech (IOBT) to Neutral from Overweight with a price target of 50c, down from $3. The firm cites the company’s intention to explore strategic opportunities to maximize shareholder value for the downgrade. While the underlying science behind IO’s T-win platform and lead candidate cylembio is promising, the company continues to face capital constraints, the analyst tells investors in a research note. Piper stepped to the sidelines, saying there’s no assur

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By